RIP1, RIP3, and MLKL Contribute to Cell Death Caused by Clostridium perfringens Enterotoxin

被引:24
|
作者
Shrestha, Archana [1 ]
Gohari, Iman Mehdizadeh [1 ]
McClane, Bruce A. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA
来源
MBIO | 2019年 / 10卷 / 06期
基金
加拿大自然科学与工程研究理事会;
关键词
Clostridium perfringens enterotoxin; apoptosis; necroptosis; RIP1; kinase; RIP3; MLKL; calpain; Clostridium perfringens; enterotoxin; A ENTEROTOXIN; NECROPTOSIS; CALPAIN; BINDING; PATHWAYS; CYTOTOXICITY; ACTIVATION; APOPTOSIS; GENE;
D O I
10.1128/mBio.02985-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium perfringens type F strains cause gastrointestinal disease when they produce a pore-forming toxin named C. perfringens enterotoxin (CPE). In human enterocyte-like Caco-2 cells, low CPE concentrations cause caspase-3-dependent apoptosis, while high CPE concentrations cause necrosis. Since necrosis or apoptosis sometimes involves receptor-interacting serine/threonine-protein kinase-1 or 3 (RIP1 or RIP3), this study examined whether those kinases are important for CPE-induced apoptosis or necrosis. Highly specific RIP1 or RIP3 inhibitors reduced both CPE-induced apoptosis and necrosis in Caco-2 cells. Those findings suggested that the form of necrosis induced by treating Caco-2 cells with high CPE concentrations involves necroptosis, which was confirmed when high, but not low, CPE concentrations were shown to induce oligomerization of mixed-lineage kinase domain-like pseudokinase (MLKL), a key late step in necroptosis. Furthermore, an MLKL oligomerization inhibitor reduced cell death caused by high, but not low, CPE concentrations. Supporting RIP1 and RIP3 involvement in CPE-induced necroptosis, inhibitors of those kinases also reduced MLKL oligomerization during treatment with high CPE concentrations. Calpain inhibitors similarly blocked MLKL oligomerization induced by high CPE concentrations, implicating calpain activation as a key intermediate in initiating CPE-induced necroptosis. In two other CPE-sensitive cell lines, i.e., Vero cells and human enterocyte-like T84 cells, low CPE concentrations also caused primarily apoptosis/late apoptosis, while high CPE concentrations mainly induced necroptosis. Collectively, these results establish that high, but not low, CPE concentrations cause necroptosis and suggest that RIP1, RIP3, MLKL, or calpain inhibitors can be explored as potential therapeutics against CPE effects in vivo. IMPORTANCE C. perfringens type F strains are a common cause of food poisoning and antibiotic-associated diarrhea. Type F strain virulence requires production of C. perfringens enterotoxin (CPE). In Caco-2 cells, high CPE concentrations cause necrosis while low enterotoxin concentrations induce apoptosis. The current study determined that receptor-interacting serine/threonine-protein kinases 1 and 3 are involved in both CPE-induced apoptosis and necrosis in Caco-2 cells, while mixed-lineage kinase domain-like pseudokinase (MLKL) oligomerization is involved in CPE-induced necrosis, thereby indicating that this form of CPE-induced cell death involves necroptosis. High CPE concentrations also caused necroptosis in T84 and Vero cells. Calpain activation was identified as a key intermediate for CPE-induced necroptosis. These results suggest inhibitors of RIP1, RIP3, MLKL oligomerization, or calpain are useful therapeutics against CPE-mediated diseases.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Life after death: RIP1 and RIP3 move beyond necroptosis
    SB Berger
    J Bertin
    PJ Gough
    [J]. Cell Death Discovery, 2
  • [2] Life after death: RIP1 and RIP3 move beyond necroptosis
    Berger, S. B.
    Bertin, J.
    Gough, P. J.
    [J]. CELL DEATH DISCOVERY, 2016, 2
  • [3] RIP1 and RIP3 contribute to Tributyltin-induced toxicity in vitro and in vivo
    Ling, Ling
    Wen, Jingjing
    Tao, Liang
    Zhao, Mengshu
    Ge, Wenhao
    Wang, Lei
    Zhang, Jianfa
    Weng, Dan
    [J]. CHEMOSPHERE, 2019, 218 : 589 - 598
  • [4] RIP1/RIP3/MLKL Mediates Myocardial Function Through Necroptosis in Experimental Autoimmune Myocarditis
    Wu, Yujing
    Zheng, Zhenzhong
    Cao, Xiantong
    Yang, Qing
    Norton, Vikram
    Adini, Avner
    Maiti, Amit K.
    Adini, Irit
    Wu, Hao
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [5] RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease
    Lin, Qing-Song
    Chen, Ping
    Wang, Wei-Xiong
    Lin, Chen-Chao
    Zhou, Yao
    Yu, Liang-Hong
    Lin, Yuan-Xiang
    Xu, Yan-Fang
    Kang, De-Zhi
    [J]. LABORATORY INVESTIGATION, 2020, 100 (03) : 503 - 511
  • [6] Distinct roles of RIP1–RIP3 hetero- and RIP3–RIP3 homo-interaction in mediating necroptosis
    X-N Wu
    Z-H Yang
    X-K Wang
    Y Zhang
    H Wan
    Y Song
    X Chen
    J Shao
    J Han
    [J]. Cell Death & Differentiation, 2014, 21 : 1709 - 1720
  • [7] Mosaic composition of RIP1–RIP3 signalling hub and its role in regulating cell death
    Xin Chen
    Rongfeng Zhu
    Jinjin Zhong
    Yongfa Ying
    Wenxin Wang
    Yating Cao
    Hanyi Cai
    Xiang Li
    Jianwei Shuai
    Jiahuai Han
    [J]. Nature Cell Biology, 2022, 24 : 471 - 482
  • [8] RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage
    Zhou, Huiling
    Liu, Lijun
    Ma, Xiaolong
    Wang, Jian
    Yang, Jinfu
    Zhou, Xinmin
    Yang, Yifeng
    Liu, Haidan
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2021, 476 (02) : 1233 - 1243
  • [9] RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage
    Huiling Zhou
    Lijun Liu
    Xiaolong Ma
    Jian Wang
    Jinfu Yang
    Xinmin Zhou
    Yifeng Yang
    Haidan Liu
    [J]. Molecular and Cellular Biochemistry, 2021, 476 : 1233 - 1243
  • [10] Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
    Yang, Heng
    Ma, Yuting
    Chen, Guo
    Zhou, Heng
    Yamazaki, Takahiro
    Klein, Christophe
    Pietrocola, Federico
    Vacchelli, Erika
    Souquere, Sylvie
    Sauvat, Allan
    Zitvogel, Laurence
    Kepp, Oliver
    Kroemer, Guido
    [J]. ONCOIMMUNOLOGY, 2016, 5 (06):